Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver for liver failure

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Jun 2025: Trial started, NCT07053488
  2. 8 Jul 2025: Trial registered, NCT07053488

The trials

NCT07053488: CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

State
Under way
Phase
Phase 1 and Phase 2
People
90 planned
Started
1 Jun 2025
Primary completion
18 Dec 2027
Arms
CRISPR-Edited Donor Liver Transplant
Results
None posted
  1. 1 Jun 2025: Trial started
  2. 8 Jul 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.